Copaxone
Total Payments
$1.1M
Transactions
156
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $59,948 | 1 | 0 |
| 2019 | $10,412 | 2 | 0 |
| 2018 | $344,956 | 64 | 0 |
| 2017 | $694,561 | 89 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.0M | 138 | 93.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,325 | 6 | 4.4% |
| Space rental or facility fees (teaching hospital only) | $27,815 | 12 | 2.5% |
Payments by Type
Research
$1.0M
138 transactions
General
$77,140
18 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| GA-9004 | Teva Pharmaceuticals USA, Inc. | $406,394 | 0 |
| Open Label Study to Evaluate the Safety of Copaxone and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone | Teva Pharmaceuticals USA, Inc. | $202,689 | 0 |
| TV44400-CNS-40083 | Teva Pharmaceuticals USA, Inc. | $83,220 | 0 |
| A Novel Study to Investigate the Effect of Copaxone (Glatiramer Acetate) 40 mg TIW on Tissue Injury and Repair in the Central Nervous System in Relapsing MS: A Multi-modal Advanced MRI, PET, and OCT Study | Teva Pharmaceuticals USA, Inc. | $59,948 | 0 |
| A Novel Study to Investigate the Effect of Copaxone? (Glatiramer Acetate) 40 mg TIW on Tissue Injury and Repair in the Central Nervous System in Relapsing MS: A Multi-modal Advanced MRI, PET, and OCT Study | Teva Pharmaceuticals USA, Inc. | $59,948 | 0 |
| A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily | Teva Pharmaceuticals USA, Inc. | $56,887 | 0 |
| Investigation of the Probiotic VSL #3 DS and in Multiple Sclerosis Untreated or Treated with Glatiramer Acetate | Teva Pharmaceuticals USA, Inc. | $55,469 | 0 |
| The value of integration of a dedicated pharmacist and specialty pharmacy into a multiple sclerosis clinic | Teva Pharmaceuticals USA, Inc. | $47,035 | 0 |
| Comparitive effects of Glatiramer Acetate and BG0012 on lymphocyte survival and metabolism | Teva Pharmaceuticals USA, Inc. | $27,997 | 0 |
| Multiple Sclerosis and Pregnancy: Moving towards a better understanding of Treatment practices by neurologists for Women with Multiple Sclerosis of Childbearing age | Teva Pharmaceuticals USA, Inc. | $12,208 | 0 |
| Multiple Sclerosis and Fatigue: Natural History, Impact and Contributory Factors | Teva Pharmaceuticals USA, Inc. | $10,530 | 0 |
| An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis | Teva Pharmaceuticals USA, Inc. | $10,412 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 4
- Transactions 156
About Copaxone
Copaxone is a drug associated with $1.1M in payments to 4 healthcare providers, recorded across 156 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2020. In 2020, $59,948 was paid across 1 transactions to 0 doctors.
The most common payment nature for Copaxone is "Unspecified" ($1.0M, 93.0% of total).
Copaxone is associated with 12 research studies, including "GA-9004" ($406,394).